Publications

PDFs of Dr. Av-Gay’s papers can be found here

Recent Publications:

• Screening of diverse marine invertebrate extracts identified Lissoclinotoxin F, Discodermin B, and other anti-Mycobacterium tuberculosis active compounds. Sahile, HA, Williams D.E., de Voogd, N.J., Ko, M., Andersen, R.J., Av-Gay Y. (2022). J Antibiotics. DOI: 10.1038/s41429-022-00507-9.
• Clionamine Analogs Stimulate Autophagy and Inhibit Mycobacterium tuberculosis Survival in Human Macrophages: Synthesis and Molecular Target Identification. Persaud R. Li S, Chao, J., Forestieri, R., Donohue, E., Zheng, X., Chao, J.T., Yashiroda Y., Patrick, BO., Loewen,C., Gingras, AC., Boone, C., Av-Gay,Y., Roberge, M., and Andersen. RJ. (2022). Cell Chemical Biology. 29:1-113
• Efficient synthesis of benzothiazinone analogues with activity against intracellular Mycobacterium tuberculosis. Richter, A., Narula, G., Rudolph, I., Seidel, R., Wagner, C., Av-Gay, Y., Imming, P. (2022).  ChemMedChem. e202100733 doi.org/10.1002/cmdc.202100733
• Apoptosis Assessment in High-Content and High-Throughput Screening Assays. Rens, C., Shapira, T., Peña-Diaz, S., Chao, D, J., Pfeifer, T., and Av-Gay Y. (2021). Biotechniques. 70(6): 309-318
• From infection niche to therapeutic target: the intracellular lifestyle of Mycobacterium tuberculosis. Rankine-Wilson L, Shapira T, Sao-Emani C, Av-Gay Y. (2021).  Microbiology (Reading): 167 (4), 001041. https://doi.org/MIC-D-20-00307
• New Approaches Against Drug-Resistant Mycobacterium tuberculosis. Editorial.  Av-Gay Y., Mori, G., Pasca, M.R., (2021). Frontiers in microbiology. 12:854.
• Roles for phthiocerol dimycocerosate lipids in Mycobacterium tuberculosis pathogenesis. Rens C, Chao JD, Sexton DL, Tocheva EI, Av-Gay Y. (2021). Microbiology (Reading). doi: 10.1099/mic.0.001042.
• BCG immunomodulation: from the ‘hygiene hypothesis’ to COVID-19. Moulson JA and Av-Gay Y. (2021).  Immunobiolgy. 226:152052. https://doi.org/10.1016/j.imbio.2020.152052
•  High-content screening of eukaryotic kinase inhibitors identify CHK2 inhibitor activity against Mycobacterium tuberculosis. Shapira T, Rankine-Wilson L, Chao J, Pichler V, Rens C, Pfeifer T, Av-Gay Y. (2020). Frontiers in microbiology. 11:2238. doi: 10.3389/fmicb.2020.553962
• MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis. Moure AL, Narula G, Sorrentino F, Bojang A, Tsui CKM, Sao Emani C, Porras-De Francisco E, Díaz B, Rebollo-López MJ, Torres-Gómez PA, López-Román EM, Camino I, Casado Castro P, Guijarro López L, Ortega F, Ballell L, Barros-Aguirre D, Remuiñán Blanco M, Av-Gay Y. (2020)  J Med Chem. 2020;63(9):4732‐4748. doi:10.1021/acs.jmedchem.0c00003
• DMN-Tre Labeling for Detection and High-Content Screening of Compounds against Intracellular Mycobacteria. Sahile HA, Rens C, Shapira T, Andersen RJ, Av-Gay Y. (2020). ACS Omega, 5: 7, 3661-3669. https://doi.org/10.1021/acsomega.9b04173
• THP-1 and Dictyostelium infection models for screening and characterization of anti-Mycobacterium abscessus hit compounds. Richter A, Shapira T, Av-Gay Y. (2019).  Antimicrob Agents Chemother https:// DOI: 10.1128/AAC.01601-19
• Phase separation and clustering of an ABC transporter in Mycobacterium tuberculosis. Heinkel F., Abraham L., Ko M., Chao J., Bach H., Hui LT., Li H., Zhua M., Mei Ling Y., Rogalski J.C. Scurlle J., Buia JM., Mayor T., Gold MR., Chouf KC., Av-Gay Y., McIntosh LP., Gsponer J., (2019). PNAS. 116(33), 16326–16331. http://doi.org/10.1073/pnas.1820683116
• Screening of preselected libraries targeting Mycobacterium abscessus for drug discovery.
  Richter A, Strauch A, Chao J, Ko M,  Av-Gay Y. Antimicrob Agents Chemother 62:e00828-18. https://doi.org/10.1128/AAC .00828-18.
• Biophysical characterization of the tandem FHA domain regulatory module from the Mycobacterium tuberculosis ABC transporter Rv1747 Heinkel F, Shen L, Richard-Greenblatt M, Gee CL, Gay LM, Okon M, Bui JM, Alber T, Av-Gay Y, Gsponer J and McIntosh LP.
  Structure 26(7):972-986.e6. doi: 10.1016/j.str.2018.04.018.
• Synthesis, antimycobacterial activity and influence on mycobacterial InhA and PknB of 12-membered cyclodepsipeptides. Laqua K, Klemm M, Richard-Greenblatt M, Richter A, Liebe L, Huang T, Lin S, Guardia A, Pérez-Herran E, Ballell L, Av-Gay Y, Imming P.
  Bioorg Med Chem. pii: S0968-0896(18)30460-7. doi: 10.1016/j.bmc.2018.04.045.

• Protein tyrosine kinase, PtkA, is required for Mycobacterium tuberculosis growth in macrophages. Wong D, Li W, Chao JD, Zhou P, Narula G, Tsui C, Ko M, Xie J, Martinez-Frailes C, Av-Gay Y. Sci Rep. 2018 Jan 9;8(1):155. doi: 10.1038/s41598-017-18547-9.

• Nitric oxide inhalations in bronchiolitis: A pilot, randomized, double-blinded, controlled trial. Tal A, Greenberg D, Av-Gay Y, Golan-Tripto I, Feinstein Y, Ben-Shimol S, Dagan R, Goldbart AD. Pediatr Pulmonol. 2018 Jan;53(1):95-102. doi: 10.1002/ppul.23905. Epub 2017 Nov 27.

• Genome Sequences of the Mycobacterium tuberculosis H37Rv-ptkA Deletion Mutant and Its Parental Strain.
  Tsui CKM, Wong D, Narula G, Gardy JL, Hsiao WWH, Av-Gay Y.
  Genome Announc. 2017 Nov 2;5(44). pii: e01156-17. doi: 10.1128/genomeA.01156-17.

• System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis.
  Zheng X, Av-Gay Y.
  J Vis Exp. 2017 Apr 5;(122). doi: 10.3791/55273.
• Nitric oxide charged catheters as a potential strategy for prevention of hospital acquired infections.
  Margel D, Mizrahi M, Regev-Shoshani G, Ko M, Moshe M, Ozalvo R, Shavit-Grievink L, Baniel J, Kedar D, Yossepowitch O, Lifshitz D, Nadu A, Greenberg D, Av-Gay Y.
  PLoS One. 2017 Apr 14;12(4):e0174443. doi: 10.1371/journal.pone.0174443. eCollection 2017.
• Epigenetic Phosphorylation Control of Mycobacterium tuberculosis Infection and Persistence.
  Richard-Greenblatt M, Av-Gay Y.
  Microbiol Spectr. 2017 Mar;5(2). doi: 10.1128/microbiolspec.TBTB2-0005-2015. Review.
• Aminorifamycins and Sporalactams Produced in Culture by a Micromonospora sp. Isolated from a Northeastern-Pacific Marine Sediment Are Potent Antibiotics.
  Williams DE, Dalisay DS, Chen J, Polishchuck EA, Patrick BO, Narula G, Ko M, Av-Gay Y, Li H, Magarvey N, Andersen RJ.
  Org Lett. 2017 Feb 17;19(4):766-769. doi: 10.1021/acs.orglett.6b03619. Epub 2017 Feb 6.
• Intracellular Growth of Bacterial Pathogens: The Role of Secreted Effector Proteins in the Control of Phagocytosed Microorganisms.
  Poirier V, Av-Gay Y.
  Microbiol Spectr. 2015 Dec;3(6). doi: 10.1128/microbiolspec.VMBF-0003-2014.
• Ergothioneine Maintains Redox and Bioenergetic Homeostasis Essential for Drug Susceptibility and Virulence of Mycobacterium tuberculosis.
  Saini V, Cumming BM, Guidry L, Lamprecht DA, Adamson JH, Reddy VP, Chinta KC, Mazorodze JH, Glasgow JN, Richard-Greenblatt M, Gomez-Velasco A, Bach H, Av-Gay Y, Eoh H, Rhee K, Steyn AJ.
  Cell Rep. 2016 Jan 26;14(3):572-85. doi: 10.1016/j.celrep.2015.12.056. Epub 2016 Jan 7.
• Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages.
  Sorrentino F, Gonzalez del Rio R, Zheng X, Presa Matilla J, Torres Gomez P, Martinez Hoyos M, Perez Herran ME, Mendoza Losana A, Av-Gay Y.
  Antimicrob Agents Chemother. 2015 Oct 26;60(1):640-5. doi: 10.1128/AAC.01920-15.
• Phosphorylation of Mycobacterium tuberculosis protein tyrosine kinase A PtkA by Ser/Thr protein kinases.
  Zhou P, Wong D, Li W, Xie J, Av-Gay Y.
  Biochem Biophys Res Commun. 2015 Nov 13;467(2):421-6. doi: 10.1016/j.bbrc.2015.09.124. Epub 2015 Sep 26.
• Regulation of Ergothioneine Biosynthesis and Its Effect on Mycobacterium tuberculosis Growth and Infectivity.
  Richard-Greenblatt M, Bach H, Adamson J, Peña-Diaz S, Li W, Steyn AJ, Av-Gay Y.
  J Biol Chem. 2015 Sep 18;290(38):23064-76. doi: 10.1074/jbc.M115.648642. Epub 2015 Jul 30.
• Immunoevasion and immunosuppression of the macrophage by Mycobacterium tuberculosis.
  Hmama Z, Peña-Díaz S, Joseph S, Av-Gay Y.
  Immunol Rev. 2015 Mar;264(1):220-32. doi: 10.1111/imr.12268. Review.

More publications can be found on PubMed, Research Gate, and Google Scholar.
A list of patents can be found here.